SEC Form 4 · accession 0001209191-19-019046
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Mar 8, 2019
Accepted (ET)
Mar 12, 2019 · 9:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 8, 2019 | S | 9,153 | $73.1786 | D | 126,799 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F4 | Mar 8, 2019 | S | 847 | $73.7114 | D | 125,952 | I | Held by the Popovits 2010 Trust |
| Common StockF5 | holding | — | — | — | 36,168 | D | ||
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on December 10, 2018.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $72.58 to $73.55.
- F4Represents weighted average sale price. Actual sale prices ranged from $73.60 to $73.88.
- F5Represents shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.